Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK6 | P43250 | 10/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 3/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.30 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10312102 | 0.90 | GRK6 (0.39) | GRK6NTRK1AURKA | |
| SCHEMBL10312197 | 0.90 | NTRK1 (0.42) | GRK6NTRK1AURKA | |
| SCHEMBL10312096 | 0.87 | MELK (0.34) | GRK6AURKAHRH4 | |
| SCHEMBL10312132 | 0.86 | NTRK1 (0.47) | NTRK1 | |
| SCHEMBL10312165 | 0.85 | NPSR1 (0.42) | GRK6NTRK1MEN1CYP1A2CYP3A4 | |
| SCHEMBL10312153 | 0.79 | PKM (0.40) | MEN1KMT2AAURKANPSR1 | |
| SCHEMBL10312114 | 0.79 | HRH4 (0.34) | NTRK1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL10312115 | 0.79 | HRH4 (0.47) | NTRK1AURKAHRH4NPSR1 | |
| SCHEMBL10312218 | 0.79 | NTRK1 (0.44) | GRK6NTRK1AURKA | |
| SCHEMBL10312078 | 0.77 | DHODH (0.41) | GRK6NTRK1AURKAHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | STK25, STK35, SGK2 | GRK6 101/4885NTRK1 482/4885MEN1 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.